Radius Health, Inc. announced that the company has entered into definitive agreements with Endo Ventures Limited, to register, commercialize, and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. Under the terms of the agreements, Paladin will pay Radius upfront and milestone payments up to approximately $8.0 million and tiered royalties up to the mid-twenties on net sales in Canada. In accordance with the terms of the agreements, Paladin will license Radius’ abaloparatide subcutaneous injection, TYMLOS, and abaloparatide novel transdermal device for the Canadian market. Paladin will be responsible for the registration distribution, sales, marketing, medical affairs, pricing and reimbursement activities in connection with abaloparatide. Radius will be responsible for supplying the drug to Paladin.